Galena Biopharma Inc (NASDAQ:GALE) is one of the leading biopharmaceutical manufacturers focusing majorly in the development of oncology and hematology therapeutics. These help address the unmet medical complications. Today, the company has come to the limelight to announce its move to engage Canaccord Genuity Group to serve as its trusted financial advisor, a move that is expected to propel the company to higher levels of financial success. It has always been the dream of this company to rise high and become one of the Top Biotech Stocks.
Recently, an announcement was made about the company establishing a strategic alternative review process and it was in that respect that Canaccord Genuity Group Inc’s assistance was sought after.
Carrying out the company sale, doing a merger with a different party and a business combination were some of the potential strategic options put in place. The company was pretty clear in its statement when it said that there was no such a thing as the strategic response alternative serving as a form of guarantee for a transaction.
At the moment, Galena hasn’t yet come up with a timetable to guide through the completion of the review process. A lot of questions regarding the matter continue to be asked; however, the Galena still continues to show unwillingness to comment on the matter. It insists that the only moment it will be able to say something constructive is when a particular transaction will be approved by Board of Directors and signed as well.
Some reliable sources have indicated that by March, Galena will move forward with the plan to announce the results associated with the forth quarter. A lot of the concerned parties are looking forward to this day to catch a glimpse of the progress that was made last year. Investors are getting more careful with where they choose to invest their money and they look forward to this day. The secret to wise investments as a matter of fact lies in the choice of the company one chooses to invest in. This company has been putting up a number of strategies to help it move forward and it goes without saying that soon it might just turn out to be one of the Best Biotech Stocks.